U.S. markets close in 51 minutes

Evaxion Biotech A/S (EVAX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.8200-0.0100 (-0.35%)
As of 01:00PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close2.8300
Bid2.8100 x 1100
Ask2.9600 x 3200
Day's Range2.8000 - 2.8700
52 Week Range1.5100 - 25.0400
Avg. Volume42,377
Market Cap67.211M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.2590
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for EVAX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Evaxion Biotech A/S
    The Argus High-Yield Model PortfolioValue stocks -- a market segment that includes high-yield stocks -- are outperforming growth stocks in 2022 for the first time since 2016. Indeed, for the past decade, the performance record has favored growth. In nine of the past 10 years, growth stocks have topped value stocks. But the tide may be turning. The rollout of COVID-19 vaccines has given a lift to some of the cyclical companies (energy companies and regional banks) that have lagged in recent quarters, and value stocks have kept up the pace with growth stocks in the past year. Now, the Federal Reserve lifting interest rates to fend off inflation, which will likely cap multiple expansion for growth companies. Regardless, the value sector is the place to achieve income. The current yield on the iShares Russell 1000 Value Index ETF is 2.1%, compared to the 0.8% current yield on the iShares Russell 1000 Growth Index ETF. For our High-Yield Theme Model Portfolio, we are seeking stocks with yields of at least 3.0%. This moves us deep into the value segment of the market.
    Fair Value
    Economic Moat
    23 hours agoArgus Research
View more
  • GlobeNewswire

    Evaxion Biotech Announces Second Quarter 2022 Financial Results and Provides Business Update

    Expanded DNA oncology vaccine program into non-small cell lung cancer, NSCLCAnnounced successful production of personalized cancer immunotherapies for melanomaAnnounced gonorrhea as second bacterial product targetEnded second quarter with cash and cash equivalents of $25.3 millionEvaxion will host webcast and conference call today, August 10, at 8:30 am EDT COPENHAGEN, Denmark, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage bio

  • GlobeNewswire

    Evaxion Biotech A/S Announces Executive Management Changes

    COPENHAGEN, Denmark, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced the following executive management changes. Lars Staal Wegner has decided to resign as the Company’s Chief Executive Officer (CEO). Dr. Wegner will remain with the Company in an advisory role to the Company’s new CEO and Board of Directors. In Dr. Wegner’s place,

  • GlobeNewswire

    Evaxion Biotech to Host Q2 2022 Corporate Update Conference Call & Webcast on August 10

    COPENHAGEN, Denmark, July 29, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announced today that it will present its second-quarter 2022 financial results on August 10 at 8.30 a.m. EDT. To dial-in for the conference call, please use the following details: US: +1-844-825-9789International: +1-412-317-5180Conference ID: 10169785 Alternatively to access th